HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lönnqvist, T. Articles by Saarinen–Pihkala, U.M. Search for Related Content PubMed PubMed Citation Articles by Lönnqvist, T. Articles by Saarinen–Pihkala, U.M. Related Collections Metabolic disease (inherited) All Clinical trials All Pediatric Clinical trials Observational study (Cohort, Case control)

Hematopoietic stem cell transplantation in infantile neuronal ceroid lipofuscinosis

From the Hospital for Children and Adolescents, Department of Child Neurology (Drs. Lönqvist and Santavuori), Department of Pediatrics (Drs. Vettenranta and Saarinen-Pihkala), Division of Hematology–Oncology and Stem Cell Transplantation, and Department of Pathology (Dr. Rapola), University of Helsinki; Hospital District of Helsinki and Uusimaa (Dr. Vanhanen), Hyvinkää Hospital Region; and Department of Radiology (Dr. Autti), Helsinki University Central Hospital, Finland.

Address correspondence and reprint requests to Dr. Tuula Lönnqvist, Department of Child Neurology, Hospital for Children and Adolescents, University of Helsinki, PO Box 280, FIN-00029 HUCH, Finland; e-mail: tuula.lonnqvist{at}hus.fi

Objective: — To study the effect of allogeneic hematopoietic stem cell transplantation (SCT) on the clinical course of infantile neuronal ceroid lipofuscinosis (INCL), a lysosomal storage disease.

Background: — INCL is a progressive encephalopathy with severe neuronal loss, especially in the cerebral and cerebellar cortex and retina. Autofluorescent lipopigments constitute the typical storage material in INCL. The disease is caused by recessive mutations in the palmitoyl protein thioesterase 1 (PPT1) gene. PPT1 is a depalmitoylating enzyme, which is transported to lysosomes through the mannose-6-phosphate receptor-mediated pathway, and participates in the lysosomal degradation of fatty acylated proteins.

Methods: — Three patients with INCL received transplants and were followed up after SCT at the Hospital for Children and Adolescents at the University of Helsinki. The first patient rejected the first graft at the age of 7 months and had mild symptoms of INCL at the second transplantation at 11 months. The two other patients were asymptomatic when they received their transplants at the age of 4 months.

Results: — PPT1 enzyme activity was normalized in peripheral leukocytes, but remained low in the CSF and resulted only in a mild and transient amelioration of the classic INCL. All patients who received transplants developed INCL by the age of 2 or 3 years.

Conclusions: — More experimental animal and cell culture studies are needed to determine the in vivo function of PPT1. SCT currently cannot be recommended as therapy for INCL.

This article has been cited by other articles:

				P Louhiala Bone marrow transplantation in the prevention of intellectual disability due to inherited metabolic disease: ethical issues J. Med. Ethics, July 1, 2009; 35(7): 415 - 418. [Abstract] [Full Text] [PDF]

				J. Tyynela, T. Autti, M. Haltia, and S. E. Mole Pirkko Santavuori (1933-2004) J Child Neurol, June 1, 2004; 19(6): 465 - 470. [PDF]

				I. Jarvela and S. B. Glueck Charting the effects of antioxidant therapy in the diseased brain: Focus on "Vitamin E deficiency and metabolic deficits in neuronal ceroid lipofuscinosis described by bioinformatics" Physiol Genomics, December 3, 2002; 11(3): 183 - 184. [Full Text] [PDF]